Betaxolol
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Betaxolol
Betaxolol: Known uses and market status in India
Summary
All candidates produced by the TxGNN model for Betaxolol (score ≥ 0.99) that can be traced to a source are already known uses. There is therefore currently no new predicted indication for this drug in India.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 0 |
| Evidence level | Not applicable |
| India Market Status | Listed in a compiled Indian medicine price dataset (3 of 3) – CDSCO approval status is not included in this data |
| Number of Listed Products | 3 (valid: 3) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
India Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 95232 | Glucoptic Eye Drop | packet of 5 ml Eye Drop | Valid |
| 29999 | Betapress 0.5% Eye Drop | packet of 5 ml Eye Drop | Valid |
| 107898 | Iobet Eye Drop | bottle of 5 ml Eye Drop | Valid |
Safety Considerations
Package insert warnings and contraindications were not available, so please refer to the package insert for those.
- Disease contraindications flagged in the knowledge graph (these come from drug-disease relationship data, not from label text, and need verification against the label):
- Respiratory: asthma (including intrinsic and allergic asthma), pulmonary emphysema, bronchial disease
- Cardiac: atrioventricular block and atrioventricular dissociation, heart cancer
- Metabolic and endocrine: diabetes mellitus, diabetic ketoacidosis, hypoglycaemia, phaeochromocytoma and other adrenal or sympathetic tumours
- Neuromuscular: myasthenia gravis and neuromuscular junction disease
- Organ disease: kidney disease, liver disease, gallbladder disease, pyoureter
- Skin: psoriasis, parapsoriasis
- Psychiatric: anxiety disorder, neurotic disorder, dysthymic disorder
- Other tumours: duodenum cancer, small intestine cancer
- Drug interactions: 173 interactions were recorded. Those listed in the compiled data are mostly moderate and include epinephrine, corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide), atropine and hyoscyamine, bupropion, morphine, acetohexamide, and calcium salts. Minor interactions include acetylsalicylic acid, aluminium hydroxide and attapulgite.
The doses and routes relevant to the predicted indication have not been assessed, and the ophthalmic route is the only one registered in India.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.